508 656
be the balance of costs for sequence analysis, use of 5-ARIs,
and surgical treatments for applying precision medicine to
active surveillance.
The use of genetically engineered mouse model (GEMM)
matching to human PCa to perform co-clinical analysis is a
very novel and intriguing approach. PCa investigations are
limited by the availability of cell lines and patient-derived
xenografts (PDX) for more precise application of drug
therapy to individual patients. This co-clinical analysis lays
a foundation for future innovative research to improve PCa
therapeutics using GEMMs that is comparable to PDX
models.
Conflicts of interest:
Christopher Evans is a consultant for Medivation,
Astellas, Janssen, and Sanofi; has research agreements with Medivation,
Astellas, and Sanofi; has material transfer agreements with Medivation,
Astellas, and Janssen; is a clinical trial investigator for Medivation,
Astella, Janssen, and Sanofi; has received institutional research support
from Ferring; and is a speaker for Medivation, Astellas, Janssen, Amgen,
and Sanofi. Joy Yang has received institutional research support from
Ferring.
References
[1]
Hyman DM, Taylor BS, Baselga J. Implementing genome-driven oncology. Cell 2017;168:584–99.[2]
Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304:1497–500.[3]
Robinson D, Van Allen EM, Wu YM, et al. Integrative clinical geno- mics of advanced prostate cancer. Cell 2015;161:1215–28.[4]
Mateo J, Carreira S, Sandhu S, et al. DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med 2015;373:1697–708.
[5]
Dutta A, Panja S, Virk R, et al. Co-clinical analysis of a genetically- engineered mouse model and human prostate cancer reveals sig- nificance of NKX3.1 expression for response to 5(-reductase inhi- bition. Eur Urol 2017;72:499–506.[6]
Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012;2:401–4.[7]
Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 2013;6:pl1.
[8]
He WW, Sciavolino PJ, Wing J, et al. A novel human prostate-specific, androgen-regulated homeobox gene (NKX3.1) that maps to 8p21, a region frequently deleted in prostate cancer. Genomics 1997;43: 69–77.
[9]
Kim MJ, Cardiff RD, Desai N, et al. Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis. Proc Natl Acad Sci U S A 2002;99:2884–9.
[10]
Wang X, Kruithof-de Julio M, Economides KD, et al. A luminal epithelial stem cell that is a cell of origin for prostate cancer. Nature 2009;461:495–500.E U R O P E A N U R O L O G Y 7 2 ( 2 0 1 7 ) 5 0 7 – 5 0 8
508